Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma.

Christa Ellen NathAndrew GriggSebastian P A RosserJane EstellElizabeth NewmanCampbell TileySundra RamanathanShir Jing HoStephen LarsenJohn GibsonPeter PresgravePeter John ShawJudith Trotman

Published in: European journal of clinical pharmacology (2022)

Test dose PK has the potential to predict subsequent HDM exposure to achieve a target AUC once melphalan administration parameters are optimised to account for stability issues in the formulation.

Keyphrases

high dose
stem cell transplantation
low dose
multiple myeloma
drug delivery
human health
risk assessment